Loading…

Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease

Saved in:

Bibliographic Details
Published in:	British journal of haematology 2018-01, Vol.180 (1), p.150-153
Main Authors:	Cohen Aubart, Fleur, Emile, Jean‐François, Maksud, Philippe, Galanaud, Damien, Cluzel, Philippe, Benameur, Neila, Aumaitre, Olivier, Amoura, Zahir, Haroche, Julien
Format:	Article
Language:	English
Subjects:	Adult Aged Azetidines - pharmacology Azetidines - therapeutic use Bioengineering cobimetinib Computer Science Computer Vision and Pattern Recognition Engineering Sciences Erdheim-Chester Disease - diagnosis Erdheim-Chester Disease - drug therapy Erdheim-Chester Disease - genetics Erdheim-Chester Disease - metabolism Erdheim‐Chester disease Fluorodeoxyglucose F18 Hematology Histiocytosis Humans Image Processing Imaging Life Sciences Male MAP Kinase Signaling System - drug effects MAP2K1 mutation Medical Imaging Middle Aged Neurobiology Neurons and Cognition Physics Piperidines - pharmacology Piperidines - therapeutic use Positron-Emission Tomography Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - genetics Signal and Image processing Treatment Outcome
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!